Predicting prostate cancer many years before diagnosis: how and why?
Evidence of reduced prostate cancer mortality from randomized trials in Europe supports early detection of prostate cancer with prostate-specific antigen (PSA). Yet PSA screening has generated considerable controversy: it is far from clear that the benefits outweigh risks, in terms of overdiagnosis...
| Autores principales: | , |
|---|---|
| Formato: | Journal article |
| Lenguaje: | English |
| Publicado: |
2012
|